Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Amphastar Pharmaceuticals, Inc. entered into Supply Agreement with Nanjing Letop Biotechnology Co., Ltd. (effective 2026-03-03).
- Action
- entry
- Agreement
- supply
- Counterparty
- Nanjing Letop Biotechnology Co., Ltd.
- Effective
- 2026-03-03
Exact text from the filing
On March 3, 2026, (the “Effective Date”), Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), the Chinese subsidiary of Amphastar Pharmaceuticals, Inc. (“Amphastar” or, the “Company”), entered into a supply agreement (the “Supply Agreement”) with Nanjing Letop Biotechnology Co., Ltd. (“Letop”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Amphastar Pharmaceuticals, Inc. amended Contract Research Amendment with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at approximately $0.6 million (effective 2026-03-03).
- Action
- amendment
- Agreement
- collaboration
- Counterparty
- Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
- Value
- approximately $0.6 million
- Effective
- 2026-03-03
Exact text from the filing
On March 3, 2026 (the “Effective Date”), Amphastar Pharmaceuticals, Inc (“Amphastar” or, the “Company”) and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”) entered into an amendment (the “Contract Research Amendment”) to the Contract Research Agreement (the “Contract Research Agreement”), originally entered into on September 15, 2025, as previously reported by the Company on a Current Report on Form 8-K filed on September 18, 2025.
View on SEC.gov